Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022-Reference-Cited by-同舟云学术

Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022

Published:2024-07-11 Issue:9 Volume:38 Page:743-751
ISSN:1172-7047
Container-title:CNS Drugs
language:en
Short-container-title:CNS Drugs

Author:

Garnier Clément,Schein Martin,Lacroix Clémence^ORCID,Jouve Elisabeth^ORCID,Soeiro Thomas^ORCID,Gentile Gaétan,Lapeyre Mestre Maryse^ORCID,Micallef Joëlle^ORCID

Publisher

Springer Science and Business Media LLC

Link

https://link.springer.com/content/pdf/10.1007/s40263-024-01095-y.pdf

Reference44 articles.

1. Résumé des Caractéristiques du Produit : Lyrica [Internet]. Available from: https://ec.europa.eu/health/documents/community-register/2022/20220921157050/anx_157050_fr.pdf

2. Reddy DS. An enigmatic role of tonic inhibition in gabapentin therapy. EBioMedicine. 2019;42:14–5.

3. Zaccara G, Gangemi P, Perucca P, Specchio L. The adverse event profile of pregabalin: a systematic review and meta-analysis of randomized controlled trials. Epilepsia. 2011;52:826–36.

4. Romach MK, Schoedel KA, Sellers EM. Human abuse liability evaluation of CNS stimulant drugs. Neuropharmacology. 2014;87:81–90.

5. Annual report on the state of the drugs problem in Europe - 2010 - EMCDDA [Internet]. Available from: https://www.emcdda.europa.eu/publications/annual-report/2010_en

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Correction to: Patterns of Pregabalin Users from Substance Abuse Treatment Facilities: Results from the French OPPIDUM Program from 2008 to 2022;CNS Drugs;2024-08-30